• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Berry Corporation (bry) - Common Stock
The Crypto Company
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

237.60 -4.88 (-2.01%)
Official Closing Price Updated: 7:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 Next >
US Stock Market Movers: Top Gainers and Losers for the Session ↗
October 29, 2026
Via Chartmill
News headline image
Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction ↗
October 29, 2026
Glaukos’ two newer launches are carrying the company, and its 2027 target may be too low. Here’s what to watch. 
Via The Motley Fool
Top US Stock Gainers and Losers for Oct. 29, 2026 ↗
October 29, 2026
Via Chartmill
Gap-Up and Gap-Down Stocks in the Oct. 29, 2026 Session ↗
October 29, 2026
Via Chartmill
Glaukos (NYSE:GKOS): High Growth Momentum Meets a Breakout Setup ↗
October 17, 2026
Via Chartmill
Glaukos (NYSE:GKOS) Passes Minervini Trend Template and High-Growth Momentum Screen ↗
September 01, 2026
Via Chartmill
GKOS (Glaukos Corp) Shows Strong Trend Template Compliance and High Growth Momentum on ChartMill ↗
June 20, 2026
Via Chartmill
Glaukos Corp (NYSE:GKOS) Shares Surge on Record Sales and Raised Guidance After Q1 Beat ↗
April 29, 2026
Via Chartmill
Premarket Gainers and Losers on Oct. 29, 2026 ↗
October 29, 2026
Via Chartmill
News headline image
Glaukos (GKOS) Q3 2026 Earnings Call Transcript ↗
October 28, 2026
Record sales and margin expansion driven by iDose TR and Epioxa launches. 
Via The Motley Fool
Topics Earnings
News headline image
Glaukos Q3 Earnings Call Highlights ↗
October 28, 2026
Glaukos (NYSE:GKOS) reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma... 
Via MarketBeat
Topics Earnings
Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules ↗
April 03, 2026
Via Chartmill
Glaukos Corp (NYSE:GKOS) Reports Record 2025 Sales but Shares Dip on Wider Loss, Conservative Outlook ↗
February 17, 2026
Via Chartmill
After-Hours Movers: LABT, NCPL Top Gainers; Fortinet, AUROW Top Losers ↗
October 28, 2026
Via Chartmill
News headline image
If You Invested $1000 In Glaukos Stock 10 Years Ago, You Would Have This Much Today ↗
September 10, 2026
Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 3.9% on an annualized basis producing an average annual return of 17.45%. Currently, Glaukos has a market capitalization of... 
Via Benzinga
News headline image
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today ↗
August 25, 2026
Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized basis producing an average annual return of 26.17%. Currently, Glaukos has a market capitalization of... 
Via Benzinga
News headline image
Glaukos (GKOS) Q2 2026 Earnings Call Transcript ↗
August 07, 2026
iDose TR drove $74M in Q2 revenue as Glaukos raised full-year guidance. 
Via The Motley Fool
Topics Earnings
News headline image
Glaukos Q2 Earnings Call Highlights ↗
July 30, 2026
Glaukos (NYSE:GKOS) reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth... 
Via MarketBeat
Topics Earnings
News headline image
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now? ↗
July 14, 2026
Disposition represented 19% of insider's equity holdings under pre-established Rule 10b5-1 trading plan. Thurman retains 43,681 shares worth approximately $6.77 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? ↗
July 08, 2026
Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions. 
Via The Motley Fool
News headline image
Glaukos (GKOS) Q1 2026 Earnings Transcript ↗
April 29, 2026
Glaukos (GKOS) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
February 19, 2026
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗
February 19, 2026
Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗
February 19, 2026
This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline. 
Via The Motley Fool
News headline image
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
February 19, 2026
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗
February 19, 2026
BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Glaukos (GKOS) Q4 2025 Earnings Call Transcript ↗
February 17, 2026
Glaukos (GKOS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Director Sells GKOS 15,000 Shares for $1.9 Million ↗
January 31, 2026
This ophthalmic device maker, focused on glaucoma solutions, reported a notable insider sale after a challenging year for its stock. 
Via The Motley Fool
Topics Regulatory Compliance
These stocks are moving in today's after hours session ↗
January 13, 2026
Via Chartmill
News headline image
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off ↗
November 06, 2025
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap